Duchenne Muscular Dystrophy Market Report 2024 (Global Edition)

Global Duchenne Muscular Dystrophy Market Report 2024 Market Size Split by Therapeutic & Treatment Type (Molecular based therapies, Steroid therapy, Others), by End-user (Hospitals/Clinics, Ambulatory...

Duchenne Muscular Dystrophy Market Report Description

We have various report editions of Duchenne Muscular Dystrophy Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Duchenne Muscular Dystrophy Market Insights Video

Competitive Landscape of the Duchenne Muscular Dystrophy Market

The majority of the revenue in the worldwide Duchenne Muscular Dystrophy market is generated by a number of large and medium-sized competitors. The market is fairly fragmented. Major players are implementing a variety of tactics, engaging in strategic alliances and contracts, mergers and acquisitions, and the development, testing, and introduction of more potent treatments for Duchenne muscular dystrophy.

June 2024: In the Phase I/II AFFINITY DUCHENNE® trial, REGENXBIO Inc. started enrolling a new cohort of boys aged 1-3 in order to assess the safety and effectiveness of RGX-202 for Duchenne muscular dystrophy. (Source: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-expansion-affinity-duchenner-trial-include ) June 2024: The FDA approved Sarepta Therapeutics' request to broaden the use of ELEVIDYS to include DMD patients who are ambulatory and older, as well as to expedite approval for non-ambulatory patients. With the announcement of its approval, Sarepta's stock increased by 40%, signifying a major win. (Source: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys ) April 2024: Positive two-year topline data from the ARCH study for the oral medication sevasemten (EDG-5506), which is intended to reduce muscle degeneration in dystrophinopathies, were released by Edgewise Therapeutics. (Source: https://www.parentprojectmd.org/edgewise-therapeutics-announces-positive-two-year-topline-results-from-arch-study-of-edg-5506/ ) January 2024: In Germany, patients with Duchenne muscular dystrophy who are four years of age or older can now get treatment with Santhera Pharmaceuticals' AGAMREE (vamorolone). This drug's introduction in Germany marks Santhera Pharmaceuticals' official entry into the biopharma industry's commercial phase. (Source: https://www.santhera.com/assets/files/press-releases/2024-01-15_AgamreeLaunch_e_final.pdf ) September 2022: Scientists at Johns Hopkins Medicine have discovered that an experimental medication, initially created to treat kidney disease patients, increases the survival rate and enhances muscle function in mice that have been genetically modified to acquire a severe type of Duchenne muscular dystrophy (DMD). (Source: https://www.sciencedaily.com/releases/2022/09/220913140852.htm )

Top Companies Market Share in Duchenne Muscular Dystrophy Industry: (In no particular order of Rank)

• F. Hoffmann-La Roche AG
• Nippon Shinyaku Co.
• Ltd
• Sarepta therapeutics
• FibroGen
• Inc
• GalaxoSmithKline plc
• PTC Therapeutics
• Santhera Pharmaceuticals Inc
• Italfarmaco S.p.A.
• Pfizer Inc.
• Wave life sciences ltd
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Duchenne Muscular Dystrophy Market

Which Region Dominates the Duchenne Muscular Dystrophy Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue. The market in North America is anticipated to grow as a consequence of several significant factors, such as the region's increasing frequency of muscular dystrophy, FDA drug approval, a robust healthcare system bolstered by favorable government regulations, medical reimbursement in the area, and planned product launches.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Duchenne Muscular Dystrophy market due to the high rate of musculoskeletal disorders in the area and the high proportion of men living there. According to the World Bank, men make up 51.96% of India's population. Furthermore, the market is anticipated to grow as a result of the robust economic expansion and continuous improvement of public healthcare services. The pharmaceutical companies operating in the region are moving their clinical trial activities to new trial sites, mostly low- and middle-income nations. Furthermore, it is expected that the high frequency of the target condition in the area will support regional market expansion.

The current report Scope analyzes Duchenne Muscular Dystrophy Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Duchenne Muscular Dystrophy Market

According to Cognitive Market Research, the global Duchenne Muscular Dystrophy market size was estimated at USD 3351.6 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1340.64 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Duchenne Muscular Dystrophy market with a market size of USD 1057.76 million in 2024 and is projected to grow at a CAGR of 10.0% during the forecast period due to an increase in investment projects, the growth of the healthcare infrastructure, and the rise in cases of Duchenne muscular dystrophy.
• The Canada Duchenne Muscular Dystrophy market had a market share of USD 160.88 million in 2024 and is projected to grow at a CAGR of 11.0% during the forecast period ascribed to developments in Duchenne muscular dystrophy technology and the existence of a strong and essential healthcare infrastructure.
• The Mexico Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 10.7% during the forecast period, with a market size of USD 122.00 million in 2024.

Europe Duchenne Muscular Dystrophy Market

According to Cognitive Market Research, the global Duchenne Muscular Dystrophy market size was estimated at USD 3351.6 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1005.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.5% from 2024 to 2031.

• The United Kingdom Duchenne Muscular Dystrophy market had a market share of USD 168.92 million in 2024 and is projected to grow at a CAGR of 11.3% during the forecast period because of the rising incidence of myelofibrosis (MF), the need for specialized treatments, and the availability of cutting-edge medical facilities.
• The France Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 92.50 million in 2024.
• According to Cognitive Market Research, the German Duchenne Muscular Dystrophy market size was valued at USD 199.09 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period as a result of growing health consciousness and rapidly rising disposable money.
• The Italy Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 9.9% during the forecast period, with a market size of USD 86.47 million in 2024.
• The Russia Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 155.85 million in 2024.
• The Spain Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 9.6% during the forecast period with a market size of USD 82.45 million in 2024
• The Luxembourg Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 10.6% during the forecast period, with a market size of USD 31.17 million in 2024.
• The Portugal Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 21.12 million in 2024.
• The Greece Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 10.8% during the forecast period, with a market size of USD 12.07 million in 2024.
• Rest of Europe's Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 9.2% during the forecast period, with a market size of USD 155.85 million in 2024.

Asia Pacific Duchenne Muscular Dystrophy Market

According to Cognitive Market Research, the global Duchenne Muscular Dystrophy market size was estimated at USD 3351.6 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 770.87 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Duchenne Muscular Dystrophy market size was valued at USD 346.89 million in 2024 and is projected to grow at a CAGR of 13.5% during the forecast period due to an increase in investment projects, the growth of the healthcare infrastructure, and the rise in cases of Duchenne muscular dystrophy.
• The Japan Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 12.5% during the forecast period, with a market size of USD 106.38 million in 2024.
• The India Duchenne Muscular Dystrophy market had a market share of USD 92.50 million in 2024 and is projected to grow at a CAGR of 1058% during the forecast period ascribed to developments in Duchenne muscular dystrophy technology and the existence of a strong and essential healthcare infrastructure.
• The South Korean Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 13.1% during the forecast period, with a market size of USD 77.09 million in 2024.
• The Australian Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD 40.09 million in 2024.
• The South East Asia Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 15.0% during the forecast period, with a market size of USD 53.19 million in 2024.
• The Rest of Asia Pacific Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 13.8% during the forecast period, with a market size of USD 54.73 million in 2024.

South America Duchenne Muscular Dystrophy Market

According to Cognitive Market Research, the global Duchenne Muscular Dystrophy market size was estimated at USD 3351.6 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 167.58 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.4% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Duchenne Muscular Dystrophy market size was valued at USD 71.72 million in 2024 and is projected to grow at a CAGR of 12.0% during the forecast period because of the rising incidence of myelofibrosis (MF), the need for specialized treatments, and the availability of cutting-edge medical facilities.
• Argentina's Duchenne Muscular Dystrophy market had a market share of USD 28.15 million in 2024 and is projected to grow at a CAGR of 12.3% during the forecast period as a result of growing health consciousness and rapidly rising disposable money.
• Colombia Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 11.2% during the forecast period, with a market size of USD 14.91 million in 2024.
• Peru Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 11.6% during the forecast period, with a market size of USD 13.74 million in 2024.
• Chile Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 12.07 million in 2024.
• The Rest of Latin America's Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 10.5% during the forecast period, with a market size of USD 26.98 million in 2024.

Middle East and Africa Duchenne Muscular Dystrophy Market

According to Cognitive Market Research, the global Duchenne Muscular Dystrophy market size was estimated at USD 3351.6 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 67.03 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2024 to 2031..

• The GCC Countries Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 12.5% during the forecast period, with a market size of USD 28.69 million in 2024 because myelofibrosis (MF) is becoming more common, specialized care is needed, and access to cutting-edge medical institutions is easier.
• The Egypt Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 12.0% during the forecast period, with a market size of USD 7.04 million in 2024.
• The South Africa Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 10.59 million in 2024 as a result of growing health consciousness and quickly rising disposable money.
• The Turkey Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 11.2% during the forecast period, with a market size of USD 5.76 million in 2024.
• The Nigeria Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 10.8% during the forecast period, with a market size of USD 7.04 million in 2024.
• The Rest of MEA Duchenne Muscular Dystrophy market is projected to witness growth at a CAGR of 10.7% during the forecast period, with a market size of USD 7.91 million in 2024.

Duchenne Muscular Dystrophy Market Analysis

Duchenne Muscular Dystrophy Market Therapeutic & treatment type Segment Analysis

According to Cognitive Market Research, steroid therapy stands out as the dominant category over the projected period because of its wide application and demonstrated ability to impede the advancement of illness. The standard of care for DMD is a steroid medication, commonly with corticosteroids like deflazacort or prednisone, to preserve muscle function and limit the disease's progression.

Molecular based therapies emerge as the fastest-growing category in the Duchenne Muscular Dystrophy market because of developments in genetic medicine and a deeper comprehension of the fundamental mechanisms driving the illness. These treatments, which are at the vanguard of changing the DMD therapy landscape, include gene therapies, exon-skipping, and CRISPR-based gene editing.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Duchenne Muscular Dystrophy Industry. Request a Free Sample PDF!

Duchenne Muscular Dystrophy Market End-user Segment Analysis

According to Cognitive Market Research, the dominant category is hospital/clinics. Hospitals and clinics provide all-inclusive care for this most common kind of muscular dystrophy. With everything they have to offer in one place, their highly skilled and knowledgeable staff makes it easy for patients to receive care. They also arrange for consultations with experts in nutrition, physical therapy, palliative care, cardiology, and pulmonology, which expedites patient care and reduces time spent away from home.

The fastest-growing category in the Duchenne Muscular Dystrophy market is ambulatory centers motivated by the demand for specialized therapeutic environments and the growing emphasis on outpatient care. Because they are more affordable and convenient than hospitals, ambulatory facilities are increasingly being used as locations for therapies and routine examinations. These centers are well-equipped to handle the continuing treatment needed by DMD patients since they have therapy facilities and cutting-edge diagnostic instruments.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion